Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Jaguar Health (JAGX) EBITDA Margin (2016 - 2025)

Jaguar Health (JAGX) has disclosed EBITDA Margin for 11 consecutive years, with 234.77% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 112.0% to 234.77% in Q3 2025 year-over-year; TTM through Sep 2025 was 252.87%, a 13258.0% increase, with the full-year FY2024 number at 280.49%, up 7082.0% from a year prior.
  • EBITDA Margin was 234.77% for Q3 2025 at Jaguar Health, up from 268.78% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 146.34% in Q4 2024 to a low of 193000.0% in Q2 2021.
  • A 5-year average of 12281.89% and a median of 328.57% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -19273315bps in 2021, then skyrocketed 19277819bps in 2022.
  • Jaguar Health's EBITDA Margin stood at 520.29% in 2021, then skyrocketed by 63bps to 191.82% in 2022, then crashed by -71bps to 328.57% in 2023, then surged by 55bps to 146.34% in 2024, then tumbled by -60bps to 234.77% in 2025.
  • Per Business Quant, the three most recent readings for JAGX's EBITDA Margin are 234.77% (Q3 2025), 268.78% (Q2 2025), and 425.52% (Q1 2025).